Published in J Infect Dis on March 01, 1985
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol (2000) 2.62
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Restricted growth of attenuated poliovirus strains in cultured cells of a human neuroblastoma. J Virol (1989) 1.53
Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A (1991) 1.52
High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol (1994) 1.52
Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol (2003) 1.33
Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. J Virol (1993) 1.30
Attenuating mutations in the poliovirus 5' untranslated region alter its interaction with polypyrimidine tract-binding protein. J Virol (1997) 1.29
Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol (2003) 1.26
Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II. J Virol (1989) 1.19
Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol (1997) 1.19
The Spatial Dynamics of Poliomyelitis in the United States: From Epidemic Emergence to Vaccine-Induced Retreat, 1910-1971. Ann Assoc Am Geogr (2005) 1.16
Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region. J Virol (2000) 1.14
Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J Virol (1997) 1.08
Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol (2004) 1.08
Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc Natl Acad Sci U S A (2010) 1.04
Patterns of polyomavirus SV40 infections and associated cancers in humans: a model. Curr Opin Virol (2012) 0.96
Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS One (2010) 0.92
Future of polio vaccines. Expert Rev Vaccines (2009) 0.91
Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ (1992) 0.90
Mass polio vaccination. BMJ (1996) 0.89
A poliovirus hybrid expressing a neutralization epitope from the major outer membrane protein of Chlamydia trachomatis is highly immunogenic. Infect Immun (1993) 0.89
Correlation between poliovirus type 1 Mahoney replication in blood cells and neurovirulence. J Virol (1996) 0.86
Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed) (1986) 0.86
Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am J Pathol (1997) 0.86
The poliomyelitis story: a scientific hegira. Yale J Biol Med (1985) 0.85
Poliomyelitis: eradication in sight. Epidemiol Infect (1992) 0.85
Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination. Microbes Infect (2014) 0.81
The Sabin live poliovirus vaccination trials in the USSR, 1959. Yale J Biol Med (1992) 0.79
Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J Clin Microbiol (2000) 0.78
Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands. J Clin Microbiol (1999) 0.78
Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol (2016) 0.78
Oral administration of live virus protects susceptible mice from developing Theiler's virus-induced demyelinating disease. Virology (2007) 0.77
Immunisation policies--successes, failures and the future. J Clin Pathol (1996) 0.75
Human enteroviruses are not the cause of neurological impairments in children at the Korle-Bu Teaching Hospital. Pan Afr Med J (2014) 0.75
Eradicating infectious disease using weakly transmissible vaccines. Proc Biol Sci (2016) 0.75
Progress in genetics and genomics of nonhuman primates. Introduction. ILAR J (2013) 0.75
Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science (1948) 19.46
IDENTIFICATION OF THE FILTRABLE, TRANSMISSIBLE NEUROLYTIC AGENT ISOLATED FROM TOXOPLASMA-INFECTED TISSUE AS A NEW PLEUROPNEUMONIA-LIKE MICROBE. Science (1938) 11.12
TOXOPLASMA AND OBLIGATE INTRACELLULAR PARASITISM. Science (1937) 6.75
ISOLATION OF A FILTRABLE, TRANSMISSIBLE AGENT WITH "NEUROLYTI" PROPERTIES FROM TOXOPLASMA-INFECTED TISSUES. Science (1938) 5.54
AN ACQUIRED RESISTANCE OF GROWING ANIMALS TO CERTAIN NEUROTROPIC VIRUSES IN THE ABSENCE OF HUMORAL ANTIBODIES OR PREVIOUS EXPOSURE TO INFECTION. J Exp Med (1936) 5.38
MICE AS CARRIERS OF PATHOGENIC PLEUROPNEUMONIA-LIKE MICROORGANISMS. Science (1939) 4.76
EXPERIMENTAL PROLIFERATIVE ARTHRITIS IN MICE PRODUCED BY FILTRABLE, PLEUROPNEUMONIA-LIKE MICROORGANISMS. Science (1939) 4.64
PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. Science (1945) 4.05
THE THERAPEUTIC EFFECTIVENESS OF A PRACTICALLY NONTOXIC NEW COMPOUND (CALCIUM AUROTHIOMALATE) IN EXPERIMENTAL, PROLIFERATIVE, CHRONIC ARTHRITIS OF MICE. Science (1940) 3.63
INSECTS AND EPIDEMIOLOGY OF POLIOMYELITIS. Science (1942) 3.59
Visceral lesions in infectious polyneuritis: (Infectious neuronitis, acute polyneuritis with facial diplegia, guillain-barré syndrome, landry's paralysis). Am J Pathol (1941) 3.52
FLIES AS CARRIERS OF POLIOMYELITIS VIRUS IN URBAN EPIDEMICS. Science (1941) 3.48
Virus-specific, labile, nonvirion antigen in herpesvirus-infected cells. Proc Natl Acad Sci U S A (1970) 2.04
Paralytic poliomyelitis: Old dogmas and new perspectives. Rev Infect Dis (1981) 1.62
Amantadine hydrochloride. Analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA (1967) 1.52
POLIOMYELITIS IN A LABORATORY WORKER EXPOSED TO THE VIRUS. Science (1941) 1.48
Mortality from pneumonia and risk conditions during influenza epidemics. High influenza morbidity during nonepidemic years. JAMA (1977) 1.40
NUTRITION AS A FACTOR IN THE DEVELOPMENT OF CONSTITUTIONAL BARRIERS TO INVOLVEMENT OF THE NERVOUS SYSTEM BY CERTAIN VIRUSES. Science (1940) 1.28
Behaviour of Chimpanzee-avirulent Poliomyelitis Viruses in Experimentally Infected Human Volunteers. Br Med J (1955) 1.23
Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA (1965) 1.20
Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses. Eur J Epidemiol (1991) 1.15
Amantadine and influenza: evaluation of conflicting reports. J Infect Dis (1978) 1.15
Herpes simplex and herpes genitalis viruses in etiology of some human cancers. Proc Natl Acad Sci U S A (1973) 1.14
Vaccination against poliomyelitis in economically underdeveloped countries. Bull World Health Organ (1980) 1.12
Perspectives on current use of some virus vaccines in the USA. Measles, rubella, poliomyelitis, and influenza in the USA: contrasts in control by vaccination. Pediatr Res (1979) 1.09
Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A (1992) 1.04
Reproductive capacity and viability at higher temperatures of various transformed hamster cell lines. J Natl Cancer Inst (1969) 0.99
Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev Infect Dis (1984) 0.98
Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control. Eur J Epidemiol (1991) 0.95
Poliomyelitis vaccination. Evaluation and direction in continuing application. Am J Clin Pathol (1978) 0.94
Increase in preexisting cellular antigen-combining groups at different times after infection with different viruses. Proc Natl Acad Sci U S A (1970) 0.93
Immunization against measles by aerosol. Rev Infect Dis (1983) 0.92
The Presence of Poliomyelitis Virus in Human Cases and Carriers During the Winter. Yale J Biol Med (1944) 0.91
Nonvirion antigens produced by herpes simplex viruses 1 and 2. Proc Natl Acad Sci U S A (1973) 0.90
Vaccine-associated poliomyelitis cases. Bull World Health Organ (1969) 0.90
MULTIPLICATION AND SPREAD OF THE VIRUS OF ST. LOUIS ENCEPHALITIS IN MICE WITH SPECIAL EMPHASIS ON ITS FATE IN THE ALIMENTARY TRACT. J Exp Med (1947) 0.88
Nature and source of mycoplasma in various tissue cultures. Ann N Y Acad Sci (1967) 0.88
High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis (1985) 0.87
CONSTITUTIONAL BARRIERS TO INVOLVEMENT OF THE NERVOUS SYSTEM BY CERTAIN VIRUSES. Science (1940) 0.86
Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. Br Med J (Clin Res Ed) (1986) 0.86
Different effects of chloramphenicol, dactinomycin, and streptovitacin A on synthesis of tumor and virion antigens in SV40 virus-infected cells. Proc Natl Acad Sci U S A (1966) 0.84
Inadequate serological surveys for immunity to poliomyelitis. Inadequate indicators of immune status of communities using oral poliovirus vaccine and inadequate guides to vaccination policy. Med J Aust (1983) 0.84
Varicella-zoster virus vaccine. JAMA (1977) 0.84
Overview and horizons in prevention of some human infectious diseases by vaccination. Am J Clin Pathol (1978) 0.83
Effectiveness of AIDS vaccines. Science (1991) 0.81
Residual paralytic poliomyelitis in a tropical region of Brazil, 1969-1977: prevalence surveys in different age groups as indicators of changing incidence. Am J Epidemiol (1983) 0.80
Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet (1982) 0.80
Genetic phenomena in experimental viral carcinogenesis. Search for such phenomena in cancers of children. Am J Dis Child (1966) 0.80
Collaboration for accelerating progress in medical research. Science (1967) 0.80
Suppression of malignancy in human cancer cells: issues and challenges. Proc Natl Acad Sci U S A (1981) 0.78
Vaccine control of poliomyelitis in the 1980s. Yale J Biol Med (1983) 0.78
My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics (1992) 0.77
Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. 1960. Bull World Health Organ (1999) 0.76
Editorial: Misery of recurrent herpes: what to do? N Engl J Med (1975) 0.76
Are the herpes simplex-genitalis viruses a cause of certain human cancers? Adv Pathobiol (1976) 0.76
Immunization: Evaluation of some currently available and prospective vaccines. JAMA (1981) 0.76
HIV vaccination dilemma. Nature (1993) 0.76
Viral hepatitis: problems of incidence and control in military personnel. Yale J Biol Med (1976) 0.75
Viral Infections of the Human Nervous System: Classification and General Considerations. Postgrad Med J (1950) 0.75
Herpes simplex-genitalis virus nonvirion antigens and their implication in certain human cancers: unconfirmed. Proc Natl Acad Sci U S A (1974) 0.75
A STUDY OF THE THERAPEUTIC MECHANISM OF ANTI-PNEUMOCOCCIC SERUM ON THE EXPERIMENTAL DERMAL PNEUMOCOCCUS INFECTION IN RABBITS : III. THE INFLUENCE OF NON-SPECIFIC FACTORS. J Exp Med (1933) 0.75
Priorities in research. Science (1993) 0.75
Round table discussion on "Unifying concepts of leukemia and related neoplasms in man and animals leading to eventual control and prevention". Concluding remarks of the chairman. Bibl Haematol (1973) 0.75
Judaism and Medicine. Perspect Biol Med (1983) 0.75
Present status of the search for a viral etiology of human cancer. Proc Rudolf Virchow Med Soc City N Y (1967) 0.75
Control of infectious diseases. Antimicrob Agents Chemother (Bethesda) (1969) 0.75
Acceptance of the Howland award. Pediatr Res (1974) 0.75
Recent studies othe possible role of viruses in human cancer. Ann Ist Super Sanita (1965) 0.75
[Vaccination against poliomyelitis in developing countries]. Salud Publica Mex (1980) 0.75
Influenza. Dev Biol Stand (1976) 0.75
[Problems of influenza vaccination]. Fortschr Med (1981) 0.75
Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses. Dev Biol Stand (1993) 0.75
LABORATORY: LABORATORY AIDS IN THE DIAGNOSIS AND SERUM THERAPY OF PNEUMOCOCCUS PNEUMONIA. Am J Public Health Nations Health (1933) 0.75
Control of infectious diseases. J Infect Dis (1970) 0.75
[Poliomyelitis: results of liver virus vaccination]. Bol Oficina Sanit Panam (1968) 0.75
Current challenges in medical practice and research. Md Med J (1992) 0.75
Proceedings: Cancer research in Israel: work of academic institutions and National Cancer Registry. Natl Cancer Inst Monogr (1974) 0.75
[Experimental suppression of the malignity of human cancer cells and absence of immunity against human cancer]. Minerva Med (1982) 0.75
Vaccination at the portal of entry of infectious agents. Dev Biol Stand (1976) 0.75
Measles, rubella, poliomyelitis, and influenza in the USA: contrasts in control by vaccination. Monogr Paediatr (1979) 0.75
Medicine and public health in Baltimore during the early years of the Sinai Hospital of Baltimore. Md Med J (1991) 0.75
Multiple sclerosis--a critique and prospective. Adv Neurol (1974) 0.75
Further Consideration of a Suggested Simple Laboratory Test for Poliomyelitis Virus. Science (1949) 0.75
Search for viral etiology of human leukemia and lymphomas: past efforts and future perspectives. Ann Ist Super Sanita (1967) 0.75
Eradication of smallpox and elimination of poliomyelitis: contrasts in strategy. Jpn J Med Sci Biol (1981) 0.75